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Impact of water intake on the courses of chronic kidney and urinary tract dis- 
eases, such as urolithiasis, urinary tract infections, chronic kidney diseases (CKD), 
autosomal dominant polycystic kidney diseases and bladder cancer, has re- 
cently been studied. It still remains controversial whether increased water intake 
slows the progression of CKD or not. However, high water intake suppresses 
plasma levels of arginine vasopressin (AVP), which is expected to be beneficial 
for the preservation of the kidney function. Previous studies suggest that water 
intake suppresses plasma levels of AVP, and high levels of AVP have been 
suggested to play deleterious roles in animal models of kidney disease. More- 
over, recent epidemic of CKD of unknown origin, which was supposed to be 
related to the insufficient water intake and chronic volume depletion, has been 
reported in Central America, further suggesting that the suppression of AVP 
by sustained water intake might be beneficial in this CKD population. Indeed, 
the data from recent studies were consistent with the view that high water intake 
is associated with slower progression of CKD. However, contradictory findings 
also exist. The intriguing effects of increased urine volume in preserving the 
glomerular filtration rate in human patients with CKD require more large and 
well-designed randomized prospective clinical trials.
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Introduction
Water is the most abundant compound on Earth’s sur-
face, covering 70 percent of the planet. In nature, water 
exists in liquid, solid, and gaseous states. It is in dynamic 
equilibrium between the liquid and gas states at standard 
temperature and pressure. At room temperature, it is a 
tasteless and odorless liquid, nearly colorless with a tint 
of blue. Many substances dissolve in water and it is com-
monly referred to as the universal solvent. Water is essen-
tial for all life on earth and makes up for more than 
60% of our bodies. It plays an important roles in physio-
logical and biochemical functions. The therapeutic bene-
fits of water were heralded in those of Classical Greece 
and late Imperial China, even as its mechanism of ther-
apeutic action remained to be determined. Impact of wa-
ter intake in the prevention of urinary system diseases 
such as uroli- thiasis, urinary tract infections, chronic kid-
ney disease (CKD), autosomal dominant polycystic kid-
ney diseases (ADPKD) and bladder cancer were studied 
recently1). In this review, we focus on the water intake 
and progression of CKD.
Water balance and the kidney
Under normal conditions, the kidneys are the primary 
organ of water balance. The weight of the kidneys are 
less than 0.5% of the total body weight (about 150 g/kid-
ney), but usual blood flow to the kidneys at rest is approx-
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imately 25% of cardiac output. Although the kidneys fil-
ter more than 150 L body fluid on a daily basis depending 
on glomerular filtration rate (GFR), less than 1% of fil-
tered fluid is actually passed into the urine. Renal water 
excretion is primarily under the control of arginine vaso-
pressin (AVP; an antidiuretic hormone) and the renin-an- 
giotensin system. Under normal circumstances, water in-
gestion in human is driven by thirst. When plasma osmola- 
lity increases or plasma volume decreases, perception of 
thirst rises2). Thirst, as a homeostatic mechanism for the 
maintenance of fluid balance and, is controlled by plasma 
osmolality and plasma volume3). Of those two signals, 
the former is the main regulator because just a 2-3% in-
crease in plasma osmolality induces a strong perception 
of thirst4), whereas plasma volume must decrease by ap-
proximately 10% to stimulate thirst5). AVP levels increase 
rapidly with small increases in plasma osmolality, and 
changes in plasma volume appear to modulate this os-
motic stimulation6). The relatively short half-life of water 
excretion (about 100 minutes), which is dependent upon 
a high renal dilution capacity, prevents water intoxication 
effectively7). The kidneys adjust excretion according to 
the variable intakes of water and solute, as well as variable 
losses of water and solutes by the lungs, skin, and gastro-
intestinal tract. In addition to hormonally mediated water 
balance, the kidneys require water for solute excretion8). 
The kidneys can concentrate and dilute urinary solutes 
from a maximum concentrating capacity of 1,400 mosm/ 
kg H2O to a minimum diluting capacity of 40 mOsm/kg 
H2O in those with normal renal function9).
The obligatory urine volume (V) can be determined for 
individuals by dividing the daily osmolar solute excretion 
(mosm/day) by the maximal urine osmolality (Uosm max):
Obligatory urine Volume (mL)=daily osmolar solute ex-
cretion (mosm)/Uosm max (mosm/kg H2O).
Thus, the requirements for urinary water loss are in-
creased as the solute load is increased. In cases of CKD, 
the failing kidneys lose the capacity to concentrate the 
urine maximally, which means that they must excrete 
more water to eliminate the solutes acquired in the diet. 
As a consequence, patients are forced by thirst to drink 
more water to cover the loss linked to solute excretion. 
However, in cases where the volume of water ingested 
cannot be excreted fully with urine output due to a defect 
in maximal urine dilutional capacity, an individual can 
enter a hyponatremic state. AVP acts at the collecting 
duct of the kidney to decrease urine volume and promote 
water retention10). On the contrary, AVP release is inhi- 
bited and the kidney increases hypotonic urinary output 
to maintain plasma osmolality and volume. AVP is a nano- 
peptide hormone that is derived from a precursor form 
synthesized in the hypothalamus. After being synthesized 
in the hypothalamus, it is transported to the neurohypo- 
physis where it is secreted in reaction to an increase in 
plasma osmolality and a decrease in effective blood vol-
ume3,11,12). Vasopressin can bind three receptor subtypes 
known as, the V1a, V1b and V2 receptors. In the kidneys, 
the V1a receptor is mainly localized in the interlobular 
arteries, the descending vasa recta, the macular densa and 
the collecting duct13-15). The V2 receptor is predominantly 
localized in the collecting duct, the macular densa and 
the thick ascending limb of Henle. Stimulations of the 
V1a receptor and the V2 receptor result in an increase 
in blood pressure by vasoconstriction and in increase of 
water reabsorption by inserting aquaporin-2 of the collec- 
ting duct3,10,14,16-19). In the rats with CKD, V2 receptor 
mRNA levels have been shown to be significantly de-
creased that indicated AVP resistance in CKD18,20).
Although vasopressin has a pivotal role in normal wa-
ter metabolism, in certain situations, it may have delete-
rious effects on the kidney by causing increased glomer-
ular pressure, renin release, hypertension and mesangial 
cell proliferation. Bouby and Fernandes21) in 2003 repor- 
ted that low hydration with sustained high levels of vaso-
pressin induces morphological and functional changes in 
the kidney. In this experiment, mild dehydration with 
sustained high levels of vasopressin impaired renal so-
dium excretion. Bouby et al.22) in 1990 showed the effect 
of high water intake on the progression of chronic renal 
failure in the experimental model of a 5/6 nephrectomized 
rat. In this experiment, they studied renal function for 
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10 weeks and kidney morphology assessed thereafter. In- 
creased water intake in high water intake (HWI) rat re-
duced solute-free water reabsorption and urine osmola- 
lity. The progressive increases in urinary protein excre- 
tion and in systolic blood pressure observed in this model 
of CKD were significantly slowed in HWI rat compared 
with normal water intake (NWI) rat. Incidence of glomer-
ulosclerosis was also reduced in HWI rat (p<0.01). Inhi- 
bition of AVP by high water intake may have slow the 
progression of chronic renal failure in this experimental 
rat model. In another study in rats with 5/6 nephrectomy, 
Sugiura et al.23) showed that high water intake ameliorates 
tubulointerstitial injury in rats with subtotal nephrecto- 
my. Urinary volume increased and urinary osmolarity de-
creased after the nephrectomy, suggesting impaired renal 
urinary concentrating capacity. Northern blot analysis 
demonstrated that transforming growth factor-beta (TGF- 
beta) mRNA expression was significantly suppressed in 
HWI rats. In situ hybridization revealed that HWI suppre- 
ssed TGF-beta mRNA expression mainly in the outer me- 
dulla. Vasopressin levels were found to be elevated com-
pared to control rats. When rats were into a high water 
intake, vasopressin levels decreased, and blood pressure, 
proteinuria and plasma creatinine were reduced.
To show the importance of vasopressin inhibition in the 
progression of CKD rat model, Bouby et al.24) made 5/6 
nephrectomized rat in genetically vasopressin-deficient Bra- 
ttleboro rats and compared it to rats with normal vasopre- 
ssin. In Brattleboro rats, compensatory renal hypertrophy 
and CKD progression were attenuated when compared to 
rats with normal vasopressin. In an experimental SIADH 
(syndrome of inappropriate antidiuretic hormone secre-
tion) model induced by continuous administration of des-
mopressin to rats, Naito et al.25) also observed the same 
renal histopathologic abnormalities, such as dilatation of 
tubules, and inflammatory cell infiltration, accompanied 
by significant increases in the relative weight of the kidney.
Water intake and progression of chronic 
kidney disease
Whether increased water intake slows the progression 
of CKD or not, still remains a controversial topic among 
the nephrology community. HWI suppresses plasma lev-
els of AVP and suppression of AVP is expected to be be- 
neficial to kidney function. Previous animal experiments 
suggest that water intake suppresses plasma levels of AVP, 
high levels of which have been suggested to play delete-
rious roles in animal models of kidney disease21-25). Re- 
cent epidemics of CKD of unknown origin in Central 
America, which is probably related to insufficient water 
intake and chronic volume depletion, were reported and 
named “Mesoamerican nephropathy”26). It occured pri-
marily in young male agricultural workers in sugar cane 
fields. The cause of the disease thus far was unknown.
Several recent observational studies have examined the 
role of water intake in CKD progression. Two large stu- 
dies recently reported that higher urine volumes27) and 
fluid intakes28) were associated with the preservation of 
renal function. Clark et al.27) found in a prospective Cana- 
dian cohort of 2,148 apparently normal participants fol-
lowed up for 6 years that the rate of estimated glomerular 
filtration rate (eGFR) decline was inversely related to in-
creased 24-hour urine volume. For each liter increase in 
24-h urine volume from <1 L to >3 L (stratified by quar-
tile), the annual percentage decline in eGFR decreased 
by 1.3, 1.0, 0.8, and 0.5 %, respectively. The adjusted 
odds ratio of developing rapid renal decline, defined as 
eGFR loss >5%/year, was 0.46 for individuals with urine 
volume >3 L/day compared with the reference group
(urine volume 1-1.9 L/day). They concluded that in this 
community-based cohort, the decline in kidney function 
was significantly slower in those with higher urine vol-
ume compared to lower urine volume. In another study, 
Strippoli et al.28) in 2011 performed two Australian cross- 
sectional population based studies. The proportion of par- 
ticipants who completed the food frequency question- 
naires (FFQ) and had GFR measures was 2,744/3,654
(75.0%) for the first and 2,476/3,508 (70.6%) for the sec-
ond survey. CKD was present in 12.4-23.5% men and 
14.9-28.7% women (mean ages 66.4-65.4 years), respec- 
tively. Participants who had the highest quintile of fluid 
intake (3.2 L/day) had a significantly lower risk of CKD 
Electrolyte Blood Press 13:46-51, 2015 • Http://Dx.Doi.Org/10.5049/Ebp.2015.13.2.46 49
Copyright © 2015 The Korean Society of Electrolyte Metabolism
(odds ratio 0.5; 95% CI 0.32 to 0.77, p for trend=0.003). 
There was a significant inverse linear association between 
self-reported daily fluid intake volume and CKD preva- 
lence. They concluded that higher intakes of fluid appear 
to protect against CKD. CKD may be preventable at 
a population level with low-cost increased fluid intake. 
Most recently, Sontrop et al.29) conducted a cross-sectio- 
nal analysis of the 2005-2006 U.S. National Health and 
Nutrition Examination Survey. They categorized total 
water intake from foods and beverages as low (<2.0
L/day), moderate (2.0-4.3 L/day) and high (>4.3 L/day) 
and found higher CKD prevalence among those with the 
lowest fluid intake (<2 L/day) versus highest total fluid 
intake (>4.3 L/day) (adjusted odds ratio 2.52; 95% CI 
0.91-6.96). Interestingly, when stratified by intake of (1) 
plain water and (2) other beverages, CKD was associated 
with low intake of plain water: adjusted OR 2.36 (95% 
CI 1.10-5.06), but not other beverages: adjusted OR 0.87 
(95% CI 0.30-2.50). Their results provide additional evi-
dence suggesting a potentially protective effect of higher 
total water intake, particularly plain water, on the kidney. 
In 2013, Clark et al.30) also conducted a six-week pilot 
study to examine the safety and feasibility of asking adults 
with CKD to increase their water intake. They randomly 
assigned 29 patients to either a hydration or a control 
group. The hydration group was asked to increase water 
intake by 1 to 1.5 L/day relative to their weight, gender, 
and 24 h urine osmolality, in addition to usual consumed 
beverages. The control group was asked to continue with 
usual fluid intake. After six weeks, the change in urine 
volume was significantly different between groups (0.9 
L/day; p=0.002) with no change in serum sodium and 
no serious adverse effects. This study provided clear evi-
dence of safety feasibility and the absence of a negative 
impact on the quality of life of the hydration intervention 
relative to the control CKD population.
However, contradictory findings were also reported 
previously. Hebert et al.31) performed a retrospective ana- 
lysis of 581 CKD patients with eGFR 25-55 mL/min in 
the Modification of Diet in Renal Disease cohort A. eGFR 
was repeatedly determined in 442 ADPKD patients and 
139 patients with CKD from other causes over an average 
interval of 2.3 years. They tested the hypothesis that urine 
volume, urine osmolality (Uosm), or both are significantly 
associated with GFR decline in patients with chronic renal 
insufficiency. Contrary to the prevailing view that water 
is beneficial in CKD, the authors reported that indivi- 
duals in the highest quartile of urine volume (>2.85 
L/day) showed a faster eGFR decline than individuals 
in the lowest quartile of urine volume (<2 L/day). The 
authors concluded that sustained high urine volume and 
low Uosm are independent risk factors for faster GFR 
decline in patients with chronic renal insufficiency. Thus, 
high fluid intake does not appear to slow renal disease 
progression in humans. They suggest that until better 
evidence becomes available, patients with chronic renal 
insufficiency should generally let their thirst guide fluid 
intake. In general, kidney transplant recipients are in-
structed to increase their daily fluid intake so as to pre-
serve kidney function. However, studies supporting this 
hypothesis are lacking. Magpantay et al.32) examined the 
effect of urine output on renal function. They observed 
in renal transplant patients with baseline eGFR of 46
mL/min that renal function decline was not different be-
tween patients who were prescribed a daily fluid intake 
of 4 L compared with patients who were prescribed 2
L daily. The authors of this study concluded that recom-
mendation of higher fluid intake does not seem to im-
prove chronic kidney transplant failure. Very recently, 
Sontrop et al.33) performed a randomized controlled pilot 
trial with 28 patients with stage 3 CKD. HWI group drink 
approximately upto 1.5 L more per day than controls for 
6 weeks and the control group was asked to maintain 
regular water intake. This increased water intake caused 
a significant decrease in plasma copeptin concentration 
among patients in the hydration group. Whether the ef-
fect of increased water intake on plasma copeptin concen-
tration is clinically significant, beneficial or sustainable 
over time is unknown at present.
Conclusion
In conclusion, despite the encouraging association be-
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tween HWI and preserved eGFR in the two large ob-
servational studies27,28), causal relationships between in-
creased water intake and reduced GFR loss among in-
dividuals with CKD remain speculative. The intriguing 
effects of increased urine volume in preserving the glo-
merular filtration rate in humans with chronic renal dis-
ease need for large well-designed randomized prospective 
clinical trials.
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